Predictive models assessing the response to ustekinumab highlight the value of therapeutic drug monitoring in Crohn’s disease
Claire Liefferinckx, Antoine Hubert, Debby Thomas, Jérémie Bottieau, Charlotte Minsart, Anneline Cremer, Leila Amininejad, François Vallée, Jean‐François Toubeau, Denis Franchimont
Topics & Concepts
MedicineUstekinumabCrohn's diseaseInternal medicineLogistic regressionReceiver operating characteristicTherapeutic drug monitoringRetrospective cohort studyDrugArea under the curveDiseasePharmacokineticsGastroenterologyPharmacologyAdalimumabInflammatory Bowel DiseaseBiosimilars and Bioanalytical MethodsRheumatoid Arthritis Research and Therapies